Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director | April 24, 2026 | April 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 24, 2026 · Filed April 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 6,751,103 |
Ending reported balance
After 2026-04-27 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-24 · Grant · Acquired 2,286 · Balance 6,741,103 F1: Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Row 2 · 2026-04-27 · Purchase · Acquired 10,000 · Balance 6,751,103 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.43 to $93.04, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.86 · Expires 2036-04-23 | Direct | 7,105 |
Reported balance
After 2026-04-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-24 · Grant · Acquired 7,105 · Balance 7,105 F4: Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectAlynne Starks 2012 Irrevocable Trust | 258 |
Reported balance
Holding disclosure · report date 2026-04-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 258 F3: Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.43 to $93.04, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.
F4: Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ST JUDE MEDICAL, LLC
Report date January 04, 2017 · Filed January 06, 2017
Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 1
1 source rowRow 1 · 2017-01-04 · Disposition to issuer · Disposed 6,315,961 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.59 · Expires 2017-12-14 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-04 · Disposition to issuer · Disposed 450,000 · Balance 0 F2: Pursuant to the Merger Agreement, this option, which was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.65 · Expires 2018-12-14 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-01-04 · Disposition to issuer · Disposed 480,000 · Balance 0 F2: Pursuant to the Merger Agreement, this option, which was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.96 · Expires 2019-12-12 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-01-04 · Disposition to issuer · Disposed 480,000 · Balance 0 F2: Pursuant to the Merger Agreement, this option, which was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.27 · Expires 2020-12-10 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-01-04 · Disposition to issuer · Disposed 367,512 · Balance 0 F2: Pursuant to the Merger Agreement, this option, which was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.41 · Expires 2021-12-10 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-01-04 · Disposition to issuer · Disposed 323,093 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.08 · Expires 2022-12-08 | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-01-04 · Disposition to issuer · Disposed 322,428 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-01-04 · Disposition to issuer · Disposed 9,693 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-01-04 · Disposition to issuer · Disposed 18,316 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F3: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.
F2: Pursuant to the Merger Agreement, this option, which was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
F3: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2018 Filed Feb 28, 2018 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 700 | $60.60 | $42,420.00 |
DisclosureSEC source: 0001179110-18-003061 · edgar.xml · nonDerivative · entry 9 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,945,948 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 100 | $60.60 | $6,059.50 |
DisclosureSEC source: 0001179110-18-003061 · edgar.xml · nonDerivative · entry 8 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,945,248 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 600 | $60.59 | $36,354.00 |
DisclosureSEC source: 0001179110-18-003061 · edgar.xml · nonDerivative · entry 7 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,945,148 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 100 | $60.58 | $6,058.00 |
DisclosureSEC source: 0001179110-18-003061 · edgar.xml · nonDerivative · entry 6 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,944,548 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 100 | $60.58 | $6,057.50 |
DisclosureSEC source: 0001179110-18-003061 · edgar.xml · nonDerivative · entry 5 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,944,448 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 400 | $60.57 | $24,228.00 |
DisclosureSEC source: 0001179110-18-003061 · edgar.xml · nonDerivative · entry 4 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,944,348 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 500 | $60.56 | $30,280.00 |
DisclosureSEC source: 0001179110-18-003061 · edgar.xml · nonDerivative · entry 3 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,943,948 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 100 | $60.53 | $6,053.00 |
DisclosureSEC source: 0001179110-18-003061 · edgar.xml · nonDerivative · entry 2 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,943,448 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 100 | $60.52 | $6,052.00 |
DisclosureSEC source: 0001179110-18-003061 · edgar.xml · nonDerivative · entry 1 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,943,348 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 107 | $60.87 | $6,512.56 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 29 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,012,839 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 1,200 | $60.86 | $73,032.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 28 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,012,732 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 293 | $60.86 | $17,830.52 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 27 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,011,532 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 1,000 | $60.85 | $60,850.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 26 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,011,239 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 100 | $60.85 | $6,084.50 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 25 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,010,239 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 1,000 | $60.84 | $60,840.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 24 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,010,139 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 600 | $60.83 | $36,498.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 23 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,009,139 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 200 | $60.82 | $12,164.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 22 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,008,539 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 400 | $60.82 | $24,326.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 21 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,008,339 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 900 | $60.81 | $54,729.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 20 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,007,939 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 100 | $60.81 | $6,080.50 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 19 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,007,039 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 400 | $60.80 | $24,320.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 18 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,006,939 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 300 | $60.80 | $18,238.50 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 17 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,006,539 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 800 | $60.79 | $48,632.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 16 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,006,239 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 400 | $60.79 | $24,314.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 15 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,005,439 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 2,100 | $60.78 | $127,638.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 14 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,005,039 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 200 | $60.78 | $12,155.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 13 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,002,939 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 2,100 | $60.77 | $127,617.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 12 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,002,739 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 600 | $60.77 | $36,459.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 11 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000,639 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 2,500 | $60.76 | $151,900.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 10 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000,039 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 175 | $60.76 | $10,632.13 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 9 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,997,539 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 2,200 | $60.75 | $133,650.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 8 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,997,364 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 1,100 | $60.75 | $66,819.50 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 7 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,995,164 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 200 | $60.74 | $12,148.50 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 6 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,994,064 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 2,000 | $60.74 | $121,480.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 5 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,993,864 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 400 | $60.74 | $24,294.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 4 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,991,864 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 2,200 | $60.73 | $133,606.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 3 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,991,464 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 1,079 | $60.73 | $65,522.28 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 2 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,989,264 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 4,900 | $60.72 | $297,528.00 |
DisclosureSEC source: 0001179110-18-003062 · edgar.xml · nonDerivative · entry 1 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,988,185 Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 23:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 400 | $60.87 | $24,348.00 |
DisclosureSEC source: 0001179110-18-003063 · edgar.xml · nonDerivative · entry 1 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,013,239 Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 21:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 336,131 | $0.00 Strike: $33.14 | $0.00 |
DisclosureSEC source: 0001179110-17-011054 · edgar.xml · derivative · entry 5 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 336,131 shares Expires 2018-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: St. Jude Medical, Inc. stock option that was converted to an Abbott stock option in connection with Abbott's acquisition of St. Jude Medical, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 21:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 168,413 | $0.00 Strike: $28.50 | $0.00 |
DisclosureSEC source: 0001179110-17-011054 · edgar.xml · derivative · entry 4 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 168,413 shares Expires 2018-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: St. Jude Medical, Inc. stock option that was converted to an Abbott stock option in connection with Abbott's acquisition of St. Jude Medical, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 21:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 336,131 | $33.14 | $11,139,381.34 |
DisclosureSEC source: 0001179110-17-011054 · edgar.xml · nonDerivative · entry 2 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,943,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 21:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 168,413 | $28.50 | $4,799,770.50 |
DisclosureSEC source: 0001179110-17-011054 · edgar.xml · nonDerivative · entry 1 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,607,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 04, 2017 Filed Jul 6, 2017 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 24,236 | $48.71 | $1,180,535.56 |
DisclosureSEC source: 0001179110-17-010183 · edgar.xml · nonDerivative · entry 1 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,438,704 Read SEC document |
| April 28, 2017 Filed May 2, 2017 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-006413 · edgar.xml · nonDerivative · entry 1 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,462,940 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F2 · balance_after: Includes a St. Jude Medical, Inc. restricted stock unit award that was converted to an Abbott award of 58,399 restricted stock units in connection with Abbott's acquisition of St. Jude Medical, in a transaction exempt from Section 16 under Rule 16b-3. The restricted stock units are vested and will settle in shares on July 4, 2017. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:07 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerRestricted Stock Units · Derivative | 18,316 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000582 · edgar.xml · derivative · entry 9 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,316 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F3 · price: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:07 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 322,428 | Not disclosed Strike: $69.08 | Not disclosed |
DisclosureSEC source: 0001179110-17-000582 · edgar.xml · derivative · entry 8 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 322,428 shares Expires 2022-12-08 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:07 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerRestricted Stock Units · Derivative | 9,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000582 · edgar.xml · derivative · entry 7 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,693 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:07 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 323,093 | Not disclosed Strike: $59.41 | Not disclosed |
DisclosureSEC source: 0001179110-17-000582 · edgar.xml · derivative · entry 6 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 323,093 shares Expires 2021-12-10 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing one year after the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 13:07 UTC | ST JUDE MEDICAL, LLC STJ · Entity 179857 | Disposition to issuerStock Options (Right to Buy) · Derivative | 367,512 | Not disclosed Strike: $35.27 | Not disclosed |
DisclosureSEC source: 0001179110-17-000582 · edgar.xml · derivative · entry 5 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 367,512 shares Expires 2020-12-10 F2 · price: Pursuant to the Merger Agreement, this option, which was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, this option, which was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.